Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Antiviral Res ; 142: 37-54, 2017 06.
Article in English | MEDLINE | ID: mdl-28322922

ABSTRACT

Many natural lectins have been reported to have antiviral activity. As some of these have been put forward as potential development candidates for preventing or treating viral infections, we have set out in this review to survey the literature on antiviral lectins. The review groups lectins by structural class and class of source organism we also detail their carbohydrate specificity and their reported antiviral activities. The review concludes with a brief discussion of several of the pertinent hurdles that heterologous proteins must clear to be useful clinical candidates and cites examples where such studies have been reported for antiviral lectins. Though the clearest path currently being followed is the use of antiviral lectins as anti-HIV microbicides via topical mucosal administration, some investigators have also found systemic efficacy against acute infections following subcutaneous administration.


Subject(s)
Antiviral Agents/antagonists & inhibitors , Lectins/antagonists & inhibitors , Virus Internalization/drug effects , Administration, Mucosal , Animals , Eukaryota/metabolism , Humans , Lectins/chemistry , Lectins/isolation & purification , Prokaryotic Cells/metabolism , Protein Conformation , Virus Diseases/prevention & control
2.
Plant Biotechnol J ; 14(6): 1427-37, 2016 06.
Article in English | MEDLINE | ID: mdl-26800650

ABSTRACT

Protein microbicides containing neutralizing antibodies and antiviral lectins may help to reduce the rate of infection with human immunodeficiency virus (HIV) if it is possible to manufacture the components in large quantities at a cost affordable in HIV-endemic regions such as sub-Saharan Africa. We expressed the antiviral lectin griffithsin (GRFT), which shows potent neutralizing activity against HIV, in the endosperm of transgenic rice plants (Oryza sativa), to determine whether rice can be used to produce inexpensive GRFT as a microbicide ingredient. The yield of (OS) GRFT in the best-performing plants was 223 µg/g dry seed weight. We also established a one-step purification protocol, achieving a recovery of 74% and a purity of 80%, which potentially could be developed into a larger-scale process to facilitate inexpensive downstream processing. (OS) GRFT bound to HIV glycans with similar efficiency to GRFT produced in Escherichia coli. Whole-cell assays using purified (OS) GRFT and infectivity assays using crude extracts of transgenic rice endosperm confirmed that both crude and pure (OS) GRFT showed potent activity against HIV and the crude extracts were not toxic towards human cell lines, suggesting they could be administered as a microbicide with only minimal processing. A freedom-to-operate analysis confirmed that GRFT produced in rice is suitable for commercial development, and an economic evaluation suggested that 1.8 kg/ha of pure GRFT could be produced from rice seeds. Our data therefore indicate that rice could be developed as an inexpensive production platform for GRFT as a microbicide component.


Subject(s)
Anti-HIV Agents/metabolism , Anti-Infective Agents/metabolism , Endosperm/genetics , HIV/drug effects , Oryza/genetics , Plant Lectins/genetics , Anti-HIV Agents/isolation & purification , Anti-Infective Agents/isolation & purification , Anti-Infective Agents/pharmacology , Cells, Cultured , Endosperm/metabolism , HeLa Cells , Humans , Oryza/metabolism , Plant Lectins/isolation & purification , Plant Lectins/metabolism , Plant Lectins/pharmacology , Plants, Genetically Modified/metabolism , Protein Folding
3.
Plant Biotechnol J ; 13(7): 884-92, 2015 Sep.
Article in English | MEDLINE | ID: mdl-25572960

ABSTRACT

There is an urgent need to provide effective anti-HIV microbicides to resource-poor areas worldwide. Some of the most promising microbicide candidates are biotherapeutics targeting viral entry. To provide biotherapeutics to poorer areas, it is vital to reduce the cost. Here, we report the production of biologically active recombinant cyanovirin-N (rCV-N), an antiviral protein, in genetically engineered soya bean seeds. Pure, biologically active rCV-N was isolated with a yield of 350 µg/g of dry seed weight. The observed amino acid sequence of rCV-N matched the expected sequence of native CV-N, as did the mass of rCV-N (11 009 Da). Purified rCV-N from soya is active in anti-HIV assays with an EC50 of 0.82-2.7 nM (compared to 0.45-1.8 nM for E. coli-produced CV-N). Standard industrial processing of soya bean seeds to harvest soya bean oil does not diminish the antiviral activity of recovered rCV-N, allowing the use of industrial soya bean processing to generate both soya bean oil and a recombinant protein for anti-HIV microbicide development.


Subject(s)
Bacterial Proteins/biosynthesis , Carrier Proteins/biosynthesis , Glycine max/genetics , Protein Engineering , Seeds/genetics , Anti-HIV Agents , Bacterial Proteins/genetics , Carrier Proteins/genetics , Seeds/metabolism , Glycine max/metabolism
4.
Biotechnol J ; 8(10): 1203-12, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23960004

ABSTRACT

Cereal seeds are versatile platforms for the production of recombinant proteins because they provide a stable environment for protein accumulation. Endogenous seed storage proteins, however, include several prolamin-type polypeptides that aggregate and crosslink via intermolecular disulfide bridges, which could potentially interact with multimeric recombinant proteins such as antibodies, which assemble in the same manner. We investigated this possibility by sequentially extracting a human antibody expressed in maize endosperm, followed by precipitation in vitro with zein. We provide evidence that a significant proportion of the antibody pool interacts with zein and therefore cannot be extracted using non-reducing buffers. Immunolocalization experiments demonstrated that antibodies targeted for secretion were instead retained within zein bodies because of such covalent interactions. Our findings suggest that the production of soluble recombinant antibodies in maize could be enhanced by eliminating or minimizing interactions with endogenous storage proteins.


Subject(s)
Edible Grain/genetics , Plantibodies/chemistry , Plantibodies/isolation & purification , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Seed Storage Proteins/chemistry , Zea mays/embryology , Antibodies, Monoclonal/chemistry , Antibodies, Monoclonal/immunology , Broadly Neutralizing Antibodies , Edible Grain/metabolism , Endosperm/genetics , Endosperm/metabolism , HIV Antibodies , Humans , Molecular Farming , Plant Proteins/metabolism , Plantibodies/immunology , Plants, Genetically Modified , Recombinant Proteins/metabolism , Seed Storage Proteins/metabolism , Seeds/growth & development , Zea mays/genetics , Zea mays/metabolism , Zein/chemistry , Zein/metabolism
5.
PLoS One ; 8(5): e64449, 2013.
Article in English | MEDLINE | ID: mdl-23700478

ABSTRACT

Hepatitis C virus (HCV) infection is a significant public health problem with over 170,000,000 chronic carriers and infection rates increasing worldwide. Chronic HCV infection is one of the leading causes of hepatocellular carcinoma which was estimated to result in ∼10,000 deaths in the United States in the year 2011. Current treatment options for HCV infection are limited to PEG-ylated interferon alpha (IFN-α), the nucleoside ribavirin and the recently approved HCV protease inhibitors telaprevir and boceprevir. Although showing significantly improved efficacy over the previous therapies, treatment with protease inhibitors has been shown to result in the rapid emergence of drug-resistant virus. Here we report the activity of two proteins, originally isolated from natural product extracts, which demonstrate low or sub-nanomolar in vitro activity against both genotype I and genotype II HCV. These proteins inhibit viral infectivity, binding to the HCV envelope glycoproteins E1 and E2 and block viral entry into human hepatocytes. In addition, we demonstrate that the most potent of these agents, the protein griffithsin, is readily bioavailable after subcutaneous injection and shows significant in vivo efficacy in reducing HCV viral titers in a mouse model system with engrafted human hepatocytes. These results indicate that HCV viral entry inhibitors can be an effective component of anti-HCV therapy and that these proteins should be studied further for their therapeutic potential.


Subject(s)
Antiviral Agents/pharmacology , Hepacivirus/drug effects , Plant Lectins/pharmacology , Animals , Antiviral Agents/administration & dosage , Antiviral Agents/chemistry , Cell Line , Chlorophyta/chemistry , Disease Models, Animal , Genotype , Hepacivirus/physiology , Hepatitis C/drug therapy , Hepatitis C/virology , Humans , Mice , Models, Molecular , Plant Lectins/administration & dosage , Plant Lectins/chemistry , Protein Binding , Protein Conformation , Rhodophyta/chemistry , Viral Envelope Proteins/metabolism , Viral Load/drug effects , Virus Internalization/drug effects , Virus Replication/drug effects
6.
Biotechnol Adv ; 29(1): 40-53, 2011.
Article in English | MEDLINE | ID: mdl-20816943

ABSTRACT

Maize (also known as corn) is a domesticated cereal grain that has been grown as food and animal feed for tens of thousands of years. It is currently the most widely grown crop in the world, and is used not only for food/feed but also to produce ethanol, industrial starches and oils. Maize is now at the beginning of a new agricultural revolution, where the grains are used as factories to synthesize high-value molecules. In this article we look at the diversity of high-value products from maize, recent technological advances in the field and the emerging regulatory framework that governs how transgenic maize plants and their products are grown, used and traded.


Subject(s)
Biotechnology/economics , Zea mays/genetics , Food , Gene Transfer Techniques , Government Regulation , Industry , Minerals , Plants, Genetically Modified , Recombinant Proteins/metabolism , Vitamins/biosynthesis , Zea mays/economics , Zea mays/metabolism
7.
Plant Cell Rep ; 30(1): 101-12, 2011 Jan.
Article in English | MEDLINE | ID: mdl-21082183

ABSTRACT

Phytocystatins are inhibitors of cysteine-proteases from plants putatively involved in plant defence based on their capability of inhibit heterologous enzymes. We have previously characterised the whole cystatin gene family members from barley (HvCPI-1 to HvCPI-13). The aim of this study was to assess the effects of barley cystatins on two phytophagous spider mites, Tetranychus urticae and Brevipalpus chilensis. The determination of proteolytic activity profile in both mite species showed the presence of the cysteine-proteases, putative targets of cystatins, among other enzymatic activities. All barley cystatins, except HvCPI-1 and HvCPI-7, inhibited in vitro mite cathepsin L- and/or cathepsin B-like activities, HvCPI-6 being the strongest inhibitor for both mite species. Transgenic maize plants expressing HvCPI-6 protein were generated and the functional integrity of the cystatin transgene was confirmed by in vitro inhibitory effect observed against T. urticae and B. chilensis protein extracts. Feeding experiments impaired on transgenic lines performed with T. urticae impaired mite development and reproductive performance. Besides, a significant reduction of cathepsin L-like and/or cathepsin B-like activities was observed when the spider mite fed on maize plants expressing HvCPI-6 cystatin. These findings reveal the potential of barley cystatins as acaricide proteins to protect plants against two important mite pests.


Subject(s)
Cystatins/genetics , Cysteine Proteases/metabolism , Hordeum/genetics , Immunity, Innate/genetics , Mites/enzymology , Plant Diseases/immunology , Zea mays/genetics , Animals , Base Sequence , Crosses, Genetic , Cystatins/pharmacology , Electrophoresis, Polyacrylamide Gel , Feeding Behavior/drug effects , Genes, Plant/genetics , Hordeum/drug effects , Immunity, Innate/drug effects , Mites/drug effects , Mites/physiology , Molecular Sequence Data , Plant Diseases/genetics , Plant Diseases/parasitology , Plants, Genetically Modified , Protein Processing, Post-Translational/drug effects , Recombinant Proteins/isolation & purification , Recombinant Proteins/pharmacology , Substrate Specificity/drug effects , Transformation, Genetic/drug effects , Zea mays/drug effects , Zea mays/parasitology
8.
Plant Mol Biol ; 73(4-5): 363-78, 2010 Jul.
Article in English | MEDLINE | ID: mdl-20354894

ABSTRACT

Multigene transformation (MGT) is becoming routine in plant biotechnology as researchers seek to generate more complex and ambitious phenotypes in transgenic plants. Every nuclear transgene requires its own promoter, so when coordinated expression is required, the introduction of multiple genes leads inevitably to two opposing strategies: different promoters may be used for each transgene, or the same promoter may be used over and over again. In the former case, there may be a shortage of different promoters with matching activities, but repetitious promoter use may in some cases have a negative impact on transgene stability and expression. Using illustrative case studies, we discuss promoter deployment strategies in transgenic plants that increase the likelihood of successful and stable multiple transgene expression.


Subject(s)
Genes, Plant/genetics , Promoter Regions, Genetic/genetics , Transformation, Genetic/genetics , Gene Expression Regulation, Plant , Gene Silencing , Time Factors
10.
Curr Opin Plant Biol ; 13(2): 219-25, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20022290

ABSTRACT

The deployment of genetically engineered (GE) crops in developing countries is regarded by some as a sinister manifestation of 'big business' in science. What is often overlooked, and sometimes even deliberately ignored by opponents of the technology, is that many researchers working in the field are not motivated by profits but by a desire to see such crops applied to humanitarian purposes. GE crops could help to address many of the world's most challenging, interrelated problems, including hunger, malnutrition, disease, and poverty. However, this potential will not be realized if the major barriers to adoption - which are political rather than technical - are not overcome.


Subject(s)
Biotechnology , Plants/genetics , Adaptation, Physiological/genetics , Humans , Immunity, Innate/genetics , Plants, Genetically Modified , Stress, Physiological/genetics
11.
Curr Pharm Des ; 16(4): 468-85, 2010.
Article in English | MEDLINE | ID: mdl-19900164

ABSTRACT

The global impact of human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS) is increasing and traditional preventative 'safe sex' strategies do not seem to be slowing the spread of this virus. With an efficacious vaccine at least a decade away, the only strategy to avoid the ever-increasing cost of highly active antiretroviral therapy (HAART) is to develop new methods that prevent virus transmission. Microbicides are topically-applied molecules that disrupt the HIV cycle and block infection. This review discusses the current state of the art in microbicide development, looking at the most clinically advanced microbicides and those at earlier development stages based on their mechanisms of action. The socioeconomic impact of microbicide use is also considered, as this will determine whether microbicides are taken up and used consistently by the target population.


Subject(s)
Anti-Infective Agents, Local/pharmacology , Anti-Infective Agents, Local/therapeutic use , HIV Infections/prevention & control , Animals , Anti-Infective Agents, Local/economics , Clinical Trials as Topic , Drug Evaluation, Preclinical , HIV Infections/epidemiology , HIV Infections/transmission , Humans
13.
Proc Natl Acad Sci U S A ; 106(19): 7762-7, 2009 May 12.
Article in English | MEDLINE | ID: mdl-19416835

ABSTRACT

Vitamin deficiency affects up to 50% of the world's population, disproportionately impacting on developing countries where populations endure monotonous, cereal-rich diets. Transgenic plants offer an effective way to increase the vitamin content of staple crops, but thus far it has only been possible to enhance individual vitamins. We created elite inbred South African transgenic corn plants in which the levels of 3 vitamins were increased specifically in the endosperm through the simultaneous modification of 3 separate metabolic pathways. The transgenic kernels contained 169-fold the normal amount of beta-carotene, 6-fold the normal amount of ascorbate, and double the normal amount of folate. Levels of engineered vitamins remained stable at least through to the T3 homozygous generation. This achievement, which vastly exceeds any realized thus far by conventional breeding alone, opens the way for the development of nutritionally complete cereals to benefit the world's poorest people.


Subject(s)
Food, Fortified , Transgenes , Zea mays/genetics , Ascorbic Acid/metabolism , Folic Acid/metabolism , Gene Transfer Techniques , Genetic Engineering/methods , Genetic Vectors , Homozygote , Models, Genetic , Plants, Genetically Modified , Vitamin A/metabolism , Vitamins , beta Carotene/metabolism
15.
Proc Natl Acad Sci U S A ; 105(10): 3727-32, 2008 Mar 11.
Article in English | MEDLINE | ID: mdl-18316741

ABSTRACT

A series of small-molecule microbicides has been developed for vaginal delivery to prevent heterosexual HIV transmission, but results from human clinical trials have been disappointing. Protein-based microbicides, such as HIV-specific monoclonal antibodies, have been considered as an alternative approach. Despite their promising safety profile and efficacy, the major drawback of such molecules is the economy of large-scale production in mammalian cells, the current system of choice. Here, we show that an alternative biomanufacturing platform is now available for one of the most promising anti-HIV antibodies (2G12). Our data show that the HIV-neutralization capability of the antibody is equal to or superior to that of the same antibody produced in CHO cells. We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world.


Subject(s)
Anti-Infective Agents/chemical synthesis , Anti-Infective Agents/economics , Antibodies, Monoclonal/biosynthesis , HIV Antibodies/biosynthesis , HIV Infections/prevention & control , HIV Infections/transmission , Administration, Intravaginal , Animals , Anti-Infective Agents/immunology , Antibodies, Monoclonal/isolation & purification , Chromatography, Affinity , Cost-Benefit Analysis , Cricetinae , Cricetulus , Drug Administration Routes , Electrophoresis, Polyacrylamide Gel , Glycopeptides/chemistry , HIV Antibodies/isolation & purification , HIV Antigens/immunology , HIV Infections/immunology , Humans , Mass Spectrometry , Molecular Weight , Neutralization Tests , Plants, Genetically Modified , Polysaccharides/analysis , Seeds/metabolism , Staphylococcal Protein A/metabolism , Zea mays/genetics
16.
Transgenic Res ; 16(3): 261-80, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17436060

ABSTRACT

Selectable marker gene systems are vital for the development of transgenic crops. Since the creation of the first transgenic plants in the early 1980s and their subsequent commercialization worldwide over almost an entire decade, antibiotic and herbicide resistance selectable marker gene systems have been an integral feature of plant genetic modification. Without them, creating transgenic crops is not feasible on purely economic and practical terms. These systems allow the relatively straightforward identification and selection of plants that have stably incorporated not only the marker genes but also genes of interest, for example herbicide tolerance and pest resistance. Bacterial antibiotic resistance genes are also crucial in molecular biology manipulations in the laboratory. An unprecedented debate has accompanied the development and commercialization of transgenic crops. Divergent policies and their implementation in the European Union on one hand and the rest of the world on the other (industrialized and developing countries alike), have resulted in disputes with serious consequences on agricultural policy, world trade and food security. A lot of research effort has been directed towards the development of marker-free transformation or systems to remove selectable markers. Such research has been in a large part motivated by perceived problems with antibiotic resistance selectable markers; however, it is not justified from a safety point of view. The aim of this review is to discuss in some detail the currently available scientific evidence that overwhelmingly argues for the safety of these marker gene systems. Our conclusion, supported by numerous studies, most of which are commissioned by some of the very parties that have taken a position against the use of antibiotic selectable marker gene systems, is that there is no scientific basis to argue against the use and presence of selectable marker genes as a class in transgenic plants.


Subject(s)
Crops, Agricultural/genetics , Plants, Genetically Modified/genetics , Plants, Genetically Modified/toxicity , Politics , Animal Feed , Animals , Crops, Agricultural/toxicity , DNA, Recombinant/metabolism , Genetic Markers , Humans , Recombinant Proteins/metabolism , Risk Assessment
SELECTION OF CITATIONS
SEARCH DETAIL
...